Taysha gets FDA rare pediatric and orphan drug designations for Rett syndrome

Taysha Gene Therapies (NASDAQ:TSHA) received FDA rare pediatric and orphan drug designations for TSHA-102 for the treatment of Rett syndrome.

Rett syndrome is a genetic neurodevelopmental disorder characterized by severe physical and intellectual impairments. TSHA-102 is designed to deliver a functional copy of the MECP2 gene as well as Taysha’s miRNA-responsive auto-regulatory element (miRARE) platform technology to control the level of MECP2 expression.

“TSHA-102 represents an important step forward in the field of gene therapy, where we are leveraging a novel regulatory platform called miRARE to prevent the overexpression of MECP2,” Steven Gray, Ph.D., Taysha’s chief scientific advisor, said in a statement.

“Our goal was to design a regulated construct that allowed us to control MECP2 expression to potentially avoid adverse events that are typically seen with unregulated gene therapies,” he added. 

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.